Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | Gut InstinctGo to article: In this issueGo to article: TSS Company InsightGo to article: TSS ABGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: The Pharma Industry BriefingGo to article: Komtur PharmaceuticalsGo to article: Komtur Pharmaceuticals Company InsightGo to article: How will the UK’s relaxed cannabis regulations impact clinical practice?Go to article: Finnair CargoGo to article: Finnair Cargo | Company InsightGo to article: Developing a new class of cancer combo drugsGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Antidepressants in the environment: combatting pharmaceutical pollutionGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: CBDepotGo to article: CBDepot Company InsightGo to article: Going digital to improve clinical trial enrolmentGo to article: BEAGo to article: Incretin combination therapy: a breakthrough for type 2 diabetes?Go to article: AlpexGo to article: Ebola in the DRC: vaccinating in a conflict zoneGo to article: Hemp IndustriesGo to article: Unither PharmaceuticalsGo to article: Data overload: turning challenges into opportunities in clinical trialsGo to article: ZenatekGo to article: Solving clinical research challenges: an IT perspectiveGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: EventsGo to article: In the next issue